Literature DB >> 20977341

Profound lack of interleukin (IL)-12/IL-23p40 in neonates born early in gestation is associated with an increased risk of sepsis.

Pascal M Lavoie1, Qing Huang, Elyse Jolette, Mihoko Whalen, Anne Monique Nuyt, Francois Audibert, David P Speert, Thierry Lacaze-Masmonteil, Hugo Soudeyns, Tobias R Kollmann.   

Abstract

BACKGROUND: Infants born prematurely are highly vulnerable to infections and also exhibit a high susceptibility to organ damage due to inflammation.
METHODS: To investigate homeostatic immune control early in life, we used advanced multiparameter flow cytometry to compare responses to multiple Toll-like receptor (TLR) ligands in single cells and mononuclear cell populations in term neonates versus preterm neonates born before 29 weeks of gestation.
RESULTS: Preterm neonates had globally attenuated TLR-stimulated interleukin (IL)-6, interferon-α, and, to a lesser extent, tumor necrosis factor-α responses but demonstrated relative preservation of anti-inflammatory IL-10 responses in monocytes and dendritic cell subtypes. Remarkably, preterm neonates were also profoundly deficient in the common IL-12 and IL-23 cytokines' p40 subunit, which is critical for immunity against a wide variety of microbial pathogens in mice. Consistent with the increased susceptibility to infections resulting from the lack of IL-12/IL-23 in human newborns, significantly lower serum p40 concentrations were observed at birth in infants who developed early-onset sepsis.
CONCLUSION: To our knowledge, this study is the first detailed analysis of multiple TLR function in neonates born extremely premature. Although attenuation of proinflammatory pathways may protect against tissue-damaging immunity early in life, this previously unrecognized p40 immune deficiency appears to result in considerably increased susceptibility to infection in human preterm newborns.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977341      PMCID: PMC2975517          DOI: 10.1086/657143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells.

Authors:  Ofer Levy; Eugénie E Suter; Richard L Miller; Michael R Wessels
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

Review 2.  Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features.

Authors:  Orchidée Filipe-Santos; Jacinta Bustamante; Ariane Chapgier; Guillaume Vogt; Ludovic de Beaucoudrey; Jacqueline Feinberg; Emmanuelle Jouanguy; Stéphanie Boisson-Dupuis; Claire Fieschi; Capucine Picard; Jean-Laurent Casanova
Journal:  Semin Immunol       Date:  2006-09-25       Impact factor: 11.130

3.  Quality assurance for polychromatic flow cytometry.

Authors:  Stephen P Perfetto; David Ambrozak; Richard Nguyen; Pratip Chattopadhyay; Mario Roederer
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 4.  Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.

Authors:  Robert A Kastelein; Christopher A Hunter; Daniel J Cua
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

5.  Characterisation of the host inflammatory response to Staphylococcus epidermidis in neonatal whole blood.

Authors:  C Härtel; I Osthues; J Rupp; B Haase; K Röder; W Göpel; E Herting; C Schultz
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-11-15       Impact factor: 5.747

6.  Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling.

Authors:  Kambis Sadeghi; Angelika Berger; Michaela Langgartner; Andrea-Romana Prusa; Michael Hayde; Kurt Herkner; Arnold Pollak; Andreas Spittler; Elisabeth Forster-Waldl
Journal:  J Infect Dis       Date:  2006-12-01       Impact factor: 5.226

7.  Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells.

Authors:  Ezra Aksoy; Valentina Albarani; Muriel Nguyen; Jean-Francois Laes; Jean-Louis Ruelle; Dominique De Wit; Fabienne Willems; Michel Goldman; Stanislas Goriely
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

8.  Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo.

Authors:  Donatella F Angelone; Michael R Wessels; Melissa Coughlin; Eugenie E Suter; Piero Valentini; Leslie A Kalish; Ofer Levy
Journal:  Pediatr Res       Date:  2006-08       Impact factor: 3.756

9.  Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells.

Authors:  Bénédicte Danis; Thaddeus C George; Stanislas Goriely; Binita Dutta; Joëlle Renneson; Laurent Gatto; Patricia Fitzgerald-Bocarsly; Arnaud Marchant; Michel Goldman; Fabienne Willems; Dominique De Wit
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

Review 10.  Induction of antigen-specific immunity in human neonates and infants.

Authors:  Christopher B Wilson; Tobias R Kollmann
Journal:  Nestle Nutr Workshop Ser Pediatr Program       Date:  2008
View more
  46 in total

1.  Pre-inflammatory mediators and lymphocyte subpopulations in preterm neonates with sepsis.

Authors:  Efthalia Hotoura; Vasileios Giapros; Ageliki Kostoula; Polixeni Spyrou; Styliani Andronikou
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies.

Authors:  Bich-Thuy T Sim; Sarah K Browne; Marguerite Vigliani; Dalila Zachary; Lindsey Rosen; Steven M Holland; Steven M Opal
Journal:  J Clin Immunol       Date:  2013-05-26       Impact factor: 8.317

3.  Regulatory T cell frequencies are increased in preterm infants with clinical early-onset sepsis.

Authors:  J Pagel; A Hartz; J Figge; C Gille; S Eschweiler; K Petersen; L Schreiter; J Hammer; C M Karsten; D Friedrich; E Herting; W Göpel; J Rupp; C Härtel
Journal:  Clin Exp Immunol       Date:  2016-06-12       Impact factor: 4.330

4.  The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells.

Authors:  Simone Schüller; Lukas Wisgrill; Kambis Sadeghi; Erich Gindl; Hanns Helmer; Peter Husslein; Angelika Berger; Andreas Spittler; Elisabeth Förster-Waldl
Journal:  Pediatr Res       Date:  2016-04-08       Impact factor: 3.756

5.  Attenuated innate immune defenses in very premature neonates during the neonatal period.

Authors:  Elizabeth A Marchant; Bernard Kan; Ashish A Sharma; Alice van Zanten; Tobias R Kollmann; Rollin Brant; Pascal M Lavoie
Journal:  Pediatr Res       Date:  2015-07-17       Impact factor: 3.756

Review 6.  Is the developmentally immature immune response in paediatric sepsis a recapitulation of immune tolerance?

Authors:  Aline B Maddux; Ivor S Douglas
Journal:  Immunology       Date:  2015-05       Impact factor: 7.397

Review 7.  Unique aspects of the perinatal immune system.

Authors:  Xiaoming Zhang; Dania Zhivaki; Richard Lo-Man
Journal:  Nat Rev Immunol       Date:  2017-06-19       Impact factor: 53.106

8.  Early inflammation in the absence of overt infection in preterm neonates exposed to intensive care.

Authors:  Brent A Chang; Qing Huang; Joanne Quan; Vann Chau; Mihoko Ladd; Eddie Kwan; Deborah E McFadden; Thierry Lacaze-Masmonteil; Steven P Miller; Pascal M Lavoie
Journal:  Cytokine       Date:  2011-09-21       Impact factor: 3.861

9.  Hierarchical maturation of innate immune defences in very preterm neonates.

Authors:  Ashish Arunkumar Sharma; Roger Jen; Rollin Brant; Mihoko Ladd; Qing Huang; Amanda Skoll; Christof Senger; Stuart E Turvey; Nico Marr; Pascal M Lavoie
Journal:  Neonatology       Date:  2014-03-06       Impact factor: 4.035

Review 10.  Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly.

Authors:  Tobias R Kollmann; Ofer Levy; Ruth R Montgomery; Stanislas Goriely
Journal:  Immunity       Date:  2012-11-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.